Forigerimod TFA (IPP-201101 TFA) is a Corrected the cell content and distribution in MRL/lpr salivary glands.
Corrected the defective of autophagy processes in SGs of MRL/lpr mice.
[1]. Aikaterini Thanou, et al. Treatment of systemic lupus erythematosus: new therapeutic avenues and blind alleys.
[2]. Sean Robinson, et al. Potential for Antigen-Specific Tolerizing Immunotherapy in Systematic Lupus Erythematosus. Front Immunol. 2021 Jul 16;12:654701.
[3]. Robert Zimmer, et al. Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial. Ann Rheum Dis. 2013 Nov;72(11):1830-5.
[4]. Baihui Li, et al. Rescue of autophagy and lysosome defects in salivary glands of MRL/lpr mice by a therapeutic phosphopeptide. J Autoimmun. 2018 Jun;90:132-145.
















